Table 1.
Characteristics of study populations from CPRD according initiation or cessation of statins for primary and secondary prevention of cardiovascular disease. Figures are numbers (percentage) unless stated otherwise
| Study populations | ||||
|---|---|---|---|---|
| Primary initiation | Secondary initiation | Primary cessation | Secondary cessation | |
| No of events* | 88 010 | 28 593 | 9 286 148 | 5 130 148 |
| No of outcomes† | 20 249 | 17 207 | 751 243 | 328 595 |
| No of patients | 70 409 | 28 593 | 457 073 | 230 610 |
| Men | 48 136 (68.4) | 16 512 (57.8) | 237 802 (52.0) | 137 776 (59.7) |
| Women | 22 237 (31.6) | 12 081 (42.2) | 218 271 (48.0) | 92 833 (40.3) |
| Indeterminate | 0 (0) | 0 (0) | 1 (0) | 1 (0) |
| Age (years)‡: | ||||
| 40-49 | 2502 (3.6) | 2396 (8.4) | 39 806 (8.7) | 7534 (3.3) |
| 50-59 | 12 537 (17.9) | 5377 (18.8) | 95 485 (20.9) | 26 533 (11.5) |
| 60-69 | 30 491 (43.3) | 7152 (25.0) | 153 395 (33.6) | 57 405 (24.9) |
| 70-79 | 21 939 (31.2) | 6306 (22.1) | 116 008 (25.4) | 73 013 (31.7) |
| ≥80 | 2904 (4.1) | 27 362 (5.8) | 52 379 (11.5) | 66 125 (28.7) |
| Median (IQR) | 66 (61-72) | 69 (58-80) | 66 (58-74) | 73 (64-81) |
| Diabetes§ | 5644 (8.0) | 2466 (8.62) | 114 910 (31.7) | 63 868 (27.7) |
IQR=interquartile range.
*No of opportunities for patients to either initiate or stop statins, either risk score >20% or incident cardiovascular event in initiation populations, or end of statin prescription in cessation populations.
†No of occurrences of initiation in initiation populations and No of occurrences of stopping in cessation populations.
‡Age at first risk score >20% or incident cardiovascular event in initiation populations and age at first prescription in study period in cessation populations.
§Diagnosis of diabetes before or within study period.